In our note from the Editor in Chief, Dr. Feder underlines the hope for better outcomes for the ravages of substance use disorders and a timely message for those impacted wildfires and other disasters.

Second generation antipsychotics (SGAs) have significant side effects, which has led us at Carlat to recommend conservative use. This research update adds to concerns about increased mortality, especially at higher doses, making conservative use of SGAs a necessity.

By successfully completing the test you will be awarded a certificate for 1 CME credit.

Dr. Capurso, Editor-in-Chief of The Carlat Addiction Treatment Report, provides a quick guide to buprenorphine prescriber criteria.

Guanfacine is a popular second-line treatment for ADHD in children and teens. But what happens as our patients age into adulthood? Does guanfacine remain an effective medication in adults with ADHD? This research update covers a study that tries to answer this question.

Where does escitalopram fit in the treatment of anxiety, depression, OCD, and other disorders of children and adolescents? We review the data and help you decide where to place escitalopram in your own practice.

There are multiple ways that we can help our patients reduce the risk of overdose. In our interview with Dr. Aaron Quiggle, we cover screening, fentanyl testing, the use of Narcan and the importance of learning to prescribe buprenorphine.

One of the most challenging problems in adolescent care is figuring out what level of care will give patients the best chance of recovery or progress. We give you a guide to decide what level of care to recommend based on your individual patient.

Most of us use methylphenidate (MPH) routinely in patients across a wide range of ages and even diagnoses. But what are the long-term side effects of MPH? This research update gives you a current understanding of the potential risks with helpful guidance on how to proceed with care.